Journal
Lung Cancer
Publication Date
4-1-2023
Volume
178
First Page
166
Last Page
171
Document Type
Open Access Publication
DOI
10.1016/j.lungcan.2023.02.008
Rights and Permissions
Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 Apr;178:166-171. doi: 10.1016/j.lungcan.2023.02.008. © 2023 Janssen Research and Development LLC. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Recommended Citation
Park, Keunchil; Govindan, Ramaswamy; and et al., "Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study." Lung Cancer. 178, 166 - 171. (2023).
https://digitalcommons.wustl.edu/oa_4/2340
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
